Open AccessA Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
Author(s) -
Adonis A. Rubio,
Maria V. Filsinger Interrante,
Benjamin N. Bell,
Clayton L. Brown,
Theodora Bruun,
Celia C. LaBranche,
David C. Montefiori,
Peter S. Kim
Publication year - 2021
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.02350-20
Subject(s) - gp41 , neutralization , virology , antibody , monoclonal antibody , biology , neutralizing antibody , heptad repeat , enfuvirtide , hiv vaccine , potency , fragment crystallizable region , glycoprotein , lentivirus , microbiology and biotechnology , epitope , human immunodeficiency virus (hiv) , virus , peptide sequence , vaccine trial , immunology , gene , in vitro , genetics , viral disease
Despite advances in antiretroviral therapy, HIV remains a global epidemic and has claimed more than 32 million lives. Accordingly, developing an effective HIV vaccine remains an urgent public health need.